XRCC1 and leukemia: In addition, when this meta-analysis was performed excluding studies with small sample sizes, the results of XRCC1 Arg399Gln were changed among colorectal cancer (recessive model: OR = 1.18, 95% CI = 0.98–1.42, Ph<0.001, I2 = 62.9%; additive model: OR = 1.17, 95% CI = 0.97–1.43, Ph<0.001, I2 = 63.7%), hepatocellular cancer (dominant model: OR = 1.35, 95% CI = 1.05–1.75, Ph = 0.035, I2 = 58.4%; additive model: OR = 1.39, 95% CI = 1.03–1.86, Ph = 0.954, I2 = 0.0%), and leukemia (dominant model: OR = 1.18, 95% CI = 0.97–1.42, Ph = 0.012, I2 = 55.8%), as shown in Table 6.